Drug Profile


Alternative Names: BEN-2001; JNJ-31001074

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Class Morpholines; Neuropsychotherapeutics; Piperazines; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder

Most Recent Events

  • 19 Jun 2017 BenevolentAl Bio plans the phase IIb CASPAR trial for Parkinson's disease (In adults, In the elderly) (PO) (NCT03194217)
  • 28 Jun 2013 No development reported - Phase-I for Attention-deficit hyperactivity disorder (in children and adolescents) in USA (PO)
  • 28 Jun 2013 No development reported - Phase-II for Attention-deficit hyperactivity disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top